JAGX
Price
$2.01
Change
-$0.02 (-0.99%)
Updated
Sep 23 closing price
Capitalization
4.37M
NBY
Price
$2.14
Change
+$0.03 (+1.42%)
Updated
Sep 23 closing price
Capitalization
12.46M
Interact to see
Advertisement

JAGX vs NBY

Header iconJAGX vs NBY Comparison
Open Charts JAGX vs NBYBanner chart's image
Jaguar Health
Price$2.01
Change-$0.02 (-0.99%)
Volume$92.16K
Capitalization4.37M
NovaBay Pharmaceuticals
Price$2.14
Change+$0.03 (+1.42%)
Volume$366.28K
Capitalization12.46M
JAGX vs NBY Comparison Chart in %
Loading...
JAGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
JAGX vs. NBY commentary
Sep 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JAGX is a Hold and NBY is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 24, 2025
Stock price -- (JAGX: $2.01 vs. NBY: $2.14)
Brand notoriety: JAGX and NBY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: JAGX: 82% vs. NBY: 4%
Market capitalization -- JAGX: $4.37M vs. NBY: $12.46M
JAGX [@Biotechnology] is valued at $4.37M. NBY’s [@Biotechnology] market capitalization is $12.46M. The market cap for tickers in the [@Biotechnology] industry ranges from $97.36B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

JAGX’s FA Score shows that 1 FA rating(s) are green whileNBY’s FA Score has 3 green FA rating(s).

  • JAGX’s FA Score: 1 green, 4 red.
  • NBY’s FA Score: 3 green, 2 red.
According to our system of comparison, NBY is a better buy in the long-term than JAGX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

JAGX’s TA Score shows that 4 TA indicator(s) are bullish while NBY’s TA Score has 5 bullish TA indicator(s).

  • JAGX’s TA Score: 4 bullish, 4 bearish.
  • NBY’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both JAGX and NBY are a good buy in the short-term.

Price Growth

JAGX (@Biotechnology) experienced а +2.03% price change this week, while NBY (@Biotechnology) price change was -2.28% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.75%. For the same industry, the average monthly price growth was +7.78%, and the average quarterly price growth was +47.65%.

Industries' Descriptions

@Biotechnology (+2.75% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NBY($12.5M) has a higher market cap than JAGX($4.37M). NBY has higher P/E ratio than JAGX: NBY (0.93) vs JAGX (0.05). NBY YTD gains are higher at: 256.073 vs. JAGX (-92.040). NBY has higher annual earnings (EBITDA): -7.05M vs. JAGX (-38.75M). NBY has more cash in the bank: 5.34M vs. JAGX (2.21M). NBY has less debt than JAGX: NBY (1.04M) vs JAGX (30.5M). JAGX has higher revenues than NBY: JAGX (11.8M) vs NBY (9.78M).
JAGXNBYJAGX / NBY
Capitalization4.37M12.5M35%
EBITDA-38.75M-7.05M550%
Gain YTD-92.040256.073-36%
P/E Ratio0.050.936%
Revenue11.8M9.78M121%
Total Cash2.21M5.34M41%
Total Debt30.5M1.04M2,927%
FUNDAMENTALS RATINGS
JAGX vs NBY: Fundamental Ratings
JAGX
NBY
OUTLOOK RATING
1..100
587
VALUATION
overvalued / fair valued / undervalued
1..100
12
Undervalued
32
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10012
PRICE GROWTH RATING
1..100
6534
P/E GROWTH RATING
1..100
991
SEASONALITY SCORE
1..100
14n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

JAGX's Valuation (12) in the Pharmaceuticals Generic industry is in the same range as NBY (32) in the Biotechnology industry. This means that JAGX’s stock grew similarly to NBY’s over the last 12 months.

JAGX's Profit vs Risk Rating (100) in the Pharmaceuticals Generic industry is in the same range as NBY (100) in the Biotechnology industry. This means that JAGX’s stock grew similarly to NBY’s over the last 12 months.

NBY's SMR Rating (12) in the Biotechnology industry is significantly better than the same rating for JAGX (100) in the Pharmaceuticals Generic industry. This means that NBY’s stock grew significantly faster than JAGX’s over the last 12 months.

NBY's Price Growth Rating (34) in the Biotechnology industry is in the same range as JAGX (65) in the Pharmaceuticals Generic industry. This means that NBY’s stock grew similarly to JAGX’s over the last 12 months.

NBY's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for JAGX (99) in the Pharmaceuticals Generic industry. This means that NBY’s stock grew significantly faster than JAGX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
JAGXNBY
RSI
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
88%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
87%
Momentum
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
89%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
85%
Advances
ODDS (%)
Bullish Trend 16 days ago
82%
Bullish Trend 1 day ago
83%
Declines
ODDS (%)
Bearish Trend 12 days ago
90%
Bearish Trend 7 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
JAGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RBBN3.920.05
+1.29%
Ribbon Communications
CRBP11.54-0.02
-0.17%
Corbus Pharmaceuticals Holdings
PBH62.98-0.62
-0.97%
Prestige Consumer Healthcare
NTRA172.83-6.36
-3.55%
Natera
INTS0.25-0.01
-5.00%
Intensity Therapeutics

JAGX and

Correlation & Price change

A.I.dvisor indicates that over the last year, JAGX has been closely correlated with CDTX. These tickers have moved in lockstep 90% of the time. This A.I.-generated data suggests there is a high statistical probability that if JAGX jumps, then CDTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JAGX
1D Price
Change %
JAGX100%
-0.99%
CDTX - JAGX
90%
Closely correlated
-2.62%
NCNA - JAGX
89%
Closely correlated
-2.99%
TAOX - JAGX
89%
Closely correlated
-2.90%
RNAC - JAGX
89%
Closely correlated
-2.29%
NBY - JAGX
88%
Closely correlated
+1.42%
More

NBY and

Correlation & Price change

A.I.dvisor indicates that over the last year, NBY has been closely correlated with CDTX. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if NBY jumps, then CDTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBY
1D Price
Change %
NBY100%
+1.42%
CDTX - NBY
93%
Closely correlated
-2.62%
NCNA - NBY
93%
Closely correlated
-2.99%
TAOX - NBY
91%
Closely correlated
-2.90%
RNAC - NBY
91%
Closely correlated
-2.29%
AGEN - NBY
90%
Closely correlated
-3.48%
More